Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03559296
Other study ID # 09.2018.466
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2018
Est. completion date August 13, 2018

Study information

Verified date August 2018
Source Marmara University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aims of this study is to determine the inter- and intra-rater reliability of SEG and SEFS grade systems for postmastectomy lymphedema.


Description:

The clinical severity of lymphedema in an extremity is generally graded according to the International Society of Lymphology (ISL) stage. Stage 0 which refers to a latent or subclinical condition where swelling is not evident despite impaired lymph transport. It may exist months or years before overt edema occurs (Stages I-III). Stage I represents an early accumulation of fluid relatively high in protein content (e.g., in comparison with "venous" edema) and subsides with limb elevation. Pitting may occur. Stage II signifies that limb elevation alone rarely reduces tissue swelling and pitting is manifest. Late in Stage II, the limb may or may not pit as tissue fibrosis supervenes. Stage III encompasses lymphostatic elephantiasis where pitting is absent and trophic skin changes such as acanthosis, fat deposits, and warty overgrowths develop. Within each Stage, severity based on volume difference can be assessed as minimal (<20% increase) in limb volume, moderate (20-40% increase), or severe (>40% increase).

Because the ISL stage mainly consists of findings achieved by physical examinations and represents the most severely affected arm, it is subjective and may not reflect the distribution and mode of progression of the disease. The characteristic skin and subcutaneous tissue changes in extremities with chronic lymphedema are caused by changes in the extracellular matrix, such as connective tissue hypertrophy, fat accumulation resulting from both fat hypertrophy and an increased number of adipocytes, and interstitial protein-rich fluid accumulation. Ultrasound has been used to assess and diagnose lymphedema related changes. Subcutaneous echogenicity (SEG) and subcutaneous echo-free space (SEFS) grade systems for postmastectomy lymphedema are developed in order to grade lymphedema objectively and to delineate the disease status more clearly. However, the reliability of SEG and SEFS has not been evaluated. The aims of this study is to determine the inter- and intra-rater reliability of SEG and SEFS grade systems for postmastectomy lymphedema. Two physiatrist (one ten-year-experienced and one five-year-experienced in musculoskeletal ultrasonography) independently and alternately will assess the subjects once for each assessment. Three days later after the initial examination, one of the physiatrists reassessed the patients. The inter- and intra-rater reliability will be determined using kappa.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date August 13, 2018
Est. primary completion date August 13, 2018
Accepts healthy volunteers
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Patients with unilateral postmastectomy lymphedema

Exclusion Criteria:

1. Bilateral lymphedema

2. The patients who had known systemic edemagenic conditions (e.g., cardiac/hepatic/renal failure, terminal cancer, on chemotherapy), and/or with cancer recurrence were excluded

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Ultrasonographic assessment of postmastectomy lymphedema
Qualitative assessment of postmastectomy lymphedema via ultrasound (Subcutaneous echogenicity (SEG) and subcutaneous echo-free space (SEFS) grade systems for postmastectomy lymphedema) and circumferential tape measures ( The circumferential measurement of affected arm at MCP joint, wrist joint, 15 below elbow joint, elbow joint 15cm above elbow point) to assess upper extremity volume

Locations

Country Name City State
Turkey Marmara University School of Medicine Department of Physical Medicine and Rehabilitation Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Marmara University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary International Society of Lymphology (ISL) stage by rater 1 stage of the clinical severity of lymphedema Day 0
Primary International Society of Lymphology (ISL) stage by rater 1 stage of the clinical severity of lymphedema Day 3
Primary International Society of Lymphology (ISL) stage by rater 2 stage of the clinical severity of lymphedema Day 0
Secondary MCP joint level affected arm The circumferential measurement of affected arm at the metacarpophalangeal joints (MCP) Day 0
Secondary MCP joint level unaffected arm The circumferential measurement of affected arm at the MCP joints Day 0
Secondary wrist joint level affected arm The circumferential measurement of affected arm at wrist joint Day 0
Secondary wrist joint level unaffected arm The circumferential measurement of affected arm at wrist joint Day 0
Secondary 15 cm below the elbow joint point affected arm The circumferential measurement of affected arm at 15 cm below the elbow joint point Day 0
Secondary 15 cm below the elbow joint point unaffected arm The circumferential measurement of affected arm at 15 cm below the elbow joint point Day 0
Secondary elbow joint point affected arm The circumferential measurement of affected arm at the elbow joint point Day 0
Secondary elbow joint point unaffected arm The circumferential measurement of unaffected arm at the elbow joint point Day 0
Secondary 15 cm above the elbow joint point affected arm The circumferential measurement of affected arm at 15 cm above the elbow joint point Day 0
Secondary 15 cm above the elbow joint point unaffected arm The circumferential measurement of affected arm at 15 cm above the elbow joint point Day 0
Secondary Affected extremity volume (mL) Lymphedema of the limbs were assessed by a single physiotherapist using the circumferential and volumetric methods before and after the treatment protocol. The circumferential upper limb measurements were carried out with the arm abducted at 30°, starting at the level of the carpometacarpal joint, every 5 cm proximal to this point along both limbs. Then, a computer program (limb volumes professional version 5.0) was used to convert these values into limb volumes in milliliters. Day 0
Secondary Unaffected extremity volume (mL) Lymphedema of the limbs were assessed by a single physiotherapist using the circumferential and volumetric methods before and after the treatment protocol. The circumferential upper limb measurements were carried out with the arm abducted at 30°, starting at the level of the carpometacarpal joint, every 5 cm proximal to this point along both limbs. Then, a computer program (limb volumes professional version 5.0) was used to convert these values into limb volumes in milliliters. Day 0
Secondary Subcutaneous echogenicity (SEG) grade by rater 1 Grade 0: No increase in echogenicity in the subcutaneous layer. Namely, the subcutaneous fat layer is observed as black. Grade 1: Diffuse increase in echogenicity, but identifiable horizontal or obliquely oriented echogenic lines caused by connective tissue bundles. Grade 2: Diffuse increase in echogenicity. Echogenic lines are not identifiable Day 0
Secondary Subcutaneous echogenicity (SEG) grade by rater 1 Grade 0: No increase in echogenicity in the subcutaneous layer. Namely, the subcutaneous fat layer is observed as black. Grade 1: Diffuse increase in echogenicity, but identifiable horizontal or obliquely oriented echogenic lines caused by connective tissue bundles. Grade 2: Diffuse increase in echogenicity. Echogenic lines are not identifiable Day 3
Secondary Subcutaneous echogenicity (SEG) grade by rater 2 Grade 0: No increase in echogenicity in the subcutaneous layer. Namely, the subcutaneous fat layer is observed as black. Grade 1: Diffuse increase in echogenicity, but identifiable horizontal or obliquely oriented echogenic lines caused by connective tissue bundles. Grade 2: Diffuse increase in echogenicity. Echogenic lines are not identifiable Day 0
Secondary Subcutaneous echo-free space (SEFS) grade by rater 1 Grade 0: No SEFS. Grade 1: Horizontally oriented (<45 degrees to the skin) SEFS only. Grade 2: Presence of vertically oriented (=45 degrees to the skin) SEFS bridging the horizontally oriented SEFSs. Day 0
Secondary Subcutaneous echo-free space (SEFS) grade by rater 1 Grade 0: No SEFS. Grade 1: Horizontally oriented (<45 degrees to the skin) SEFS only. Grade 2: Presence of vertically oriented (=45 degrees to the skin) SEFS bridging the horizontally oriented SEFSs. Day 3
Secondary Subcutaneous echo-free space (SEFS) grade by rater 2 Grade 0: No SEFS. Grade 1: Horizontally oriented (<45 degrees to the skin) SEFS only. Grade 2: Presence of vertically oriented (=45 degrees to the skin) SEFS bridging the horizontally oriented SEFSs. Day 0
See also
  Status Clinical Trial Phase
Completed NCT02250898 - Massage for Post Breast Surgery N/A
Active, not recruiting NCT05441943 - Lymphaticovenous Anastomosis as Treatment for Lymphedema N/A